Syndax Pharmaceuticals, Inc. is a medium-risk biopharmaceutical company based in the United States, specializing in developing combination therapies for various cancer indications. Their product pipeline includes entinostat, SNDX-6352, and SNDX-6352, an anti-CSF-1R monoclonal antibody, aimed at enhancing the immune response to tumors sensitive to immunotherapy. With a focus on environment, sustainability, and governance (ESG), Syndax Pharmaceuticals is a leader in the pharmaceutical industry.